CODX - Co-Diagnostics, Inc.
3.0400 +0.12 (4.11%)
After hours: 7:59PM EST
| Previous Close | 3.3200 |
| Open | 3.2200 |
| Bid | 3.0100 x 3200 |
| Ask | 3.0200 x 1200 |
| Day's Range | 2.8300 - 3.3200 |
| 52 Week Range | 0.6940 - 4.2400 |
| Volume | 6,450,293 |
| Avg. Volume | 4,007,155 |
| Market Cap | 63.046M |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4050 |
| Earnings Date | Aug 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.00 |
- GuruFocus.com
The Wuhan Virus and Research-Focused Biotech Companies
With the spread of the new coronavirus from Wuhan, investors should consider investing in smaller biotech and pharma players Continue reading...
- GlobeNewswire
Co-Diagnostics (NASDAQ:CODX) Helping to Mitigate Global Economic Risk
As the world continues to worry about the novel coronavirus Covid-19 and investors begin to understand the potential impact this fast-spreading outbreak may have on China’s economy (and, by extension, the world), Co-Diagnostics Inc. (CODX), a Utah-based molecular diagnostics company, recently announced it had tested and launched its coronavirus test as a tool to help researchers and scientists slow the spread of infection. Exporters around the world are also feeling the pinch with demand for luxury items such as Louis Vuitton, Brazilian beef and French and Chilean wine, all of which are facing a huge drop in Chinese demand.
- Business Wire
Co-Diagnostics Announces Closing of $10.2 Million Registered Direct Offering Priced At-the-Market
Co-Diagnostics announces closing of $10.2 Million registered direct offering priced at-the-market
- Business Wire
Co-Diagnostics, Inc. to Present its Rapid Response to New Coronavirus in Washington D.C. Conference
Co-Diagnostics to present its rapid response to new coronavirus, plus infectious disease initiative, in Washington D.C. conference.
- MarketWatch
Coronavirus update: 1,018 deaths, a new case in San Diego, 195 evacuees expected to leave quarantine
A passenger who was repatriated from Wuhan, China, on a U.S. flight and has been in quarantine in San Diego is the latest individual in the U.S. to test positive for the coronavirus, according to media reports.
- Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 11, 2020: DISH, HAS, SHOP, CODX, FB
Benzinga Pro's Stocks To Watch For Tuesday DISH Network (DISH) - The stock was up more than 5% amid a report a U.S. judge will rule in favor of a Sprint (S) , T-Mobile (TMUS) merger on Tuesday. With ...
- Business Wire
Co-Diagnostics Announces $10.2 Million Registered Direct Offering Priced At-the-Market
Co-Diagnostics announces $10.2 Million registered direct offering priced at-the-market
- Benzinga
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...
- Business Wire
Co-Diagnostics, Inc. Announces Sales of New Coronavirus Test
Co-Diagnostics, Inc. announces sales of new coronavirus Test
- Business Wire
Co-Diagnostics, Inc. Announces Launch of Test for New Coronavirus
Co-Diagnostics, Inc. announces launch of test for new coronavirus; product launch and rapid development facilitated by proprietary design platform
- Business Wire
Co-Diagnostics Inc to Discuss New Coronavirus Test During GenomeWeb Webinar on Feb 5
Co-Diagnostics Inc to discuss new coronavirus test during GenomeWebinar on Feb 5, as well as multiplex applications for vector control solutions
- MarketWatch
Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries
President Donald Trump’s coronavirus task force on Friday announced a series of actions aimed at stemming the spread of the coronavirus outbreaks, including declaring a public-health emergency in the U.S.
- Business Wire
Co-Diagnostics, Inc. Announces Successful Initial Verification of Novel Coronavirus Test
Co-Diagnostics Inc announces successful initial verification of novel coronavirus test
- Zacks
The Wining Sector & Its Top Stocks in Virus-Infected January
January has turned out great for biotech stocks thanks to the coronavirus outbreak as well as a general upbeat trend.
- Business Wire
Co-Diagnostics, Inc. CEO Interviewed on Fox Business with Maria Bartiromo as Coronavirus Concerns Rise
Co-Diagnostics Inc CEO interviewed on Fox Business with Maria Bartiromo as coronavirus concerns rise
- MarketWatch
Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports
A nearly weeklong rally for vaccine and diagnostics developers looking to capitalize on the coronavirus outbreak ended on Tuesday.
- Business Wire
Co-Diagnostics Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market
Co-Diagnostics Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market
- Business Wire
Co-Diagnostics Inc CEO Discusses Novel Coronavirus with CNBC Squawk Box Asia
Co-Diagnostics CEO discusses novel coronavirus with CNBC Squawk Box Asia, including importance of accurate diagnostics and test announced last week
- MarketWatch
CDC officials say coronavirus is similar to SARS, no new U.S. cases reported
At least 110 people in 26 states have been identified as persons under investigation for coronavirus, Centers for Disease Control and Prevention officials said Monday.
- Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Mon., Jan. 27, 2020: DHI, NIO, JNPR, CODX, WHR
Benzinga Pro's Stocks To Watch For Monday D.R. Horton (DHI) - Shares traded down less than a percent following better-than-expected Q1 results and raised FY20 guidance. Also in the Homebuilder space, ...
- MarketWatch
Vaccine, diagnostics stocks rise again on spreading coronavirus
Shares of a handful of vaccine makers, diagnostics companies and manufacturers of medical supplies, like masks, rallied again in premarket trading on Monday over growing public concern about the new coronavirus. This includes Co-Diagnostics Inc. , up 42%; NanoViricides Inc. , up 29%; Allied Healthcare Products Inc. , up 22%; Inovio Pharmaceuticals Inc. , up 24%; and Novavax Inc. , up 13%. The Centers for Disease Control and Prevention said Sunday that there are now five confirmed cases in the U.S., all of whom had traveled to Wuhan, the city in China where the virus was first identified. Chinese health officials have said that more than 2,700 people have been sickened and at least 80 people died, according to The Wall Street Journal. Market concerns have sent global stocks and U.S. futures tumbling on Monday. The S&P 500 and the Dow Jones Industrial Average are both 1% over the last week.
- MarketWatch
Second coronavirus patient identified, extent and duration of airport screening to be ‘re-evaluated’
The two U.S. residents who have been diagnosed with the new coronavirus had both traveled to Wuhan City, China, and arrived in the United States this month with no symptoms.
- Zacks
Coronavirus Spooks Global Markets: Winners and Losers
So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.
- MarketWatch
Co-Diagnostics' stock tumbles after stock sale agreement priced at 29% discount
Shares of Co-Diagnostics Inc. tumbled 16% in premarket trading Friday, after the molecular diagnostics company took advantage of the prior session's big rally to enter into a stock sale agreement. The company said it agreed to sell 3,448,278 shares, representing about 20% of the shares outstanding, to institutional investors at $1.45 a share, which was 28.6% below Thursday's closing price of $2.03 but 28.3% above Wednesday's closing price of $1.13. Co-Diagnostics's stock had rocketed 80% on Thursday on trading volume of 36.1 million shares, after the company said it had "completed principle design work" for a test to screen the Wuhan coronavirus. The stock has nearly doubled (up 99%) over the past three months through Thursday, while the S&P 500 has gained 10.5%.
- Business Wire
Co-Diagnostics Announces $5.0 Million Registered Direct Offering Priced At-the-Market
Co-Diagnostics announces $5.0 Million registered direct offering, following news about beginning work on a test for the new coronavirus.
